FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review

TOKYO and CAMBRIDGE, Mass., Jan 26, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai’s…

Fujitsu to support Mizuho Financial Group’s human capital disclosure with a non-financial information collection and disclosure support service

KAWASAKI, Japan, Jan 26, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited today announced the introduction of FUJITSU Sustainability Solution Eco Track (Eco Track), a non-financial information collection and disclosure support service for Mizuho Financial Group, Inc. (hereinafter Mizuho) to assist with human capital disclosure in its sustainability management.…